Antenatal screening for Down's syndrome estimates a woman's risk of having an aVected pregnancy on the basis of factors found to be associated with Down's syndrome-that is, maternal age, serum concentrations of biochemical markers, and ultrasound measurements. The widely used triple test is based on maternal serum fetoprotein ( FP), unconjugated oestriol (uE3), and human chorionic gonadotropin (hCG) concentrations in the second trimester of pregnancy. 1 In the first trimester, fetal nuchal translucency (NT), measured by ultrasonography, can be used alone 2 or in combination with maternal serum pregnancy associated plasma protein-A (PAPP-A) and the free subunit of human chorionic gonadotropin (free -hCG). 3 Recently, Wald and colleagues 4 described a new screening method based on the integration of sequential measurements of first and second trimester markers into a single test. This "integrated test" is supposed to detect more cases of Down's syndrome with a much lower false positive rate than other tests currently available. The estimates of the integrated test's performance are based on there being little or no correlation between the first and second trimester markers used. This is supported by work by Lam and colleagues, 5 and from preliminary data of our own, based on 246 unaVected pregnancies. We have now extended our series to include 749 pregnancies on which first and second trimester markers were available. patients at our institution, with pregnancies of between 10 and 14 weeks' gestation, had NT measurement; a blood sample was also taken for PAPP-A and free -hCG assay. Many of the women (1453) chose to have a triple test at their local hospital, spontaneously miscarried, or had invasive testing. Indications for invasive diagnostic testing were maternal age > 35 years, NT > 3 mm, history of a previous chromosomally abnormal fetus, and family history of genetic or metabolic abnormalities. The remaining 749 women (median age 30 years) also had a second trimester triple test (hCG, uE3, FP) at our institution. All marker levels were expressed as multiples of the gestation specific median, log 10 transformed, and Spearman's correlation coeYcients were calculated for each pair of markers (table 1) .
Antenatal screening for Down's syndrome estimates a woman's risk of having an aVected pregnancy on the basis of factors found to be associated with Down's syndrome-that is, maternal age, serum concentrations of biochemical markers, and ultrasound measurements. The widely used triple test is based on maternal serum fetoprotein ( FP), unconjugated oestriol (uE3), and human chorionic gonadotropin (hCG) concentrations in the second trimester of pregnancy. 1 In the first trimester, fetal nuchal translucency (NT), measured by ultrasonography, can be used alone 2 or in combination with maternal serum pregnancy associated plasma protein-A (PAPP-A) and the free subunit of human chorionic gonadotropin (free -hCG). 3 Recently, Wald and colleagues 4 described a new screening method based on the integration of sequential measurements of first and second trimester markers into a single test. This "integrated test" is supposed to detect more cases of Down's syndrome with a much lower false positive rate than other tests currently available. The estimates of the integrated test's performance are based on there being little or no correlation between the first and second trimester markers used. This is supported by work by Lam and colleagues, 5 and from preliminary data of our own, based on 246 unaVected pregnancies. We have now extended our series to include 749 pregnancies on which first and second trimester markers were available.
Methods and results
Our dataset was derived as follows: between January 1996 and February 1998, 2202 patients at our institution, with pregnancies of between 10 and 14 weeks' gestation, had NT measurement; a blood sample was also taken for PAPP-A and free -hCG assay. Many of the women (1453) chose to have a triple test at their local hospital, spontaneously miscarried, or had invasive testing. Indications for invasive diagnostic testing were maternal age > 35 years, NT > 3 mm, history of a previous chromosomally abnormal fetus, and family history of genetic or metabolic abnormalities. The remaining 749 women (median age 30 years) also had a second trimester triple test (hCG, uE3, FP) at our institution. All marker levels were expressed as multiples of the gestation specific median, log 10 transformed, and Spearman's correlation coeYcients were calculated for each pair of markers (table 1) .
Conclusions
The results show that no significant correlation exists between the markers, except for the expected positive correlation between first trimester free -hCG and second trimester hCG measurements. These findings support the hypothesis that the integration of first and second trimester markers and maternal age could achieve a better detection rate for Down's syndrome than currently available methods. 
